JP5755566B2 - アミド系インスリンプロドラッグ - Google Patents

アミド系インスリンプロドラッグ Download PDF

Info

Publication number
JP5755566B2
JP5755566B2 JP2011542484A JP2011542484A JP5755566B2 JP 5755566 B2 JP5755566 B2 JP 5755566B2 JP 2011542484 A JP2011542484 A JP 2011542484A JP 2011542484 A JP2011542484 A JP 2011542484A JP 5755566 B2 JP5755566 B2 JP 5755566B2
Authority
JP
Japan
Prior art keywords
alkyl
group
insulin
chain
seq
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
JP2011542484A
Other languages
English (en)
Japanese (ja)
Other versions
JP2012512901A5 (enExample
JP2012512901A (ja
Inventor
ディマルキ，リチャード，ディー．
コウ，ビンビン
チェン，シュジャン
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Indiana University Research and Technology Corp
Original Assignee
Indiana University Research and Technology Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Indiana University Research and Technology Corp filed Critical Indiana University Research and Technology Corp
Publication of JP2012512901A publication Critical patent/JP2012512901A/ja
Publication of JP2012512901A5 publication Critical patent/JP2012512901A5/ja
Application granted granted Critical
Publication of JP5755566B2 publication Critical patent/JP5755566B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/62—Insulins
    • C07K14/622—Insulins at least 1 amino acid in D-form
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/28—Insulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/62—Insulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/62—Insulins
    • C07K14/625—Extraction from natural sources

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Diabetes (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Endocrinology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Toxicology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Emergency Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
JP2011542484A 2008-12-19 2009-12-18 アミド系インスリンプロドラッグ Expired - Fee Related JP5755566B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US13921808P 2008-12-19 2008-12-19
US61/139,218 2008-12-19
PCT/US2009/068716 WO2010080609A1 (en) 2008-12-19 2009-12-18 Amide-based insulin prodrugs

Publications (3)

Publication Number Publication Date
JP2012512901A JP2012512901A (ja) 2012-06-07
JP2012512901A5 JP2012512901A5 (enExample) 2013-02-21
JP5755566B2 true JP5755566B2 (ja) 2015-07-29

Family

ID=42316748

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2011542484A Expired - Fee Related JP5755566B2 (ja) 2008-12-19 2009-12-18 アミド系インスリンプロドラッグ

Country Status (7)

Country Link
US (1) US8697632B2 (enExample)
EP (1) EP2376521B1 (enExample)
JP (1) JP5755566B2 (enExample)
CN (1) CN102245624B (enExample)
AU (1) AU2009335715B2 (enExample)
CA (1) CA2744558A1 (enExample)
WO (1) WO2010080609A1 (enExample)

Families Citing this family (63)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009099763A1 (en) 2008-01-30 2009-08-13 Indiana University Research And Technology Corporation Ester-based peptide prodrugs
EP2676673B1 (en) 2008-06-17 2016-11-16 Indiana University Research and Technology Corporation Glucagon/glp-1 receptor co-agonists
KR20150116912A (ko) 2008-12-15 2015-10-16 질랜드 파마 에이/에스 글루카곤 유사체
AU2008365559B2 (en) 2008-12-15 2016-02-25 Zealand Pharma A/S Glucagon analogues
MX2011006314A (es) 2008-12-15 2011-09-22 Zealand Pharma As Analogos de glucagon.
BRPI0823379A2 (pt) 2008-12-15 2015-07-14 Zealand Pharma As Análogos de glucagon
WO2010071807A1 (en) 2008-12-19 2010-06-24 Indiana University Research And Technology Corporation Amide based glucagon superfamily peptide prodrugs
IN2012DN00377A (enExample) 2009-06-16 2015-08-21 Univ Indiana Res & Tech Corp
AP3329A (en) 2009-07-13 2015-06-30 Zealand Pharma As Acylated glucagon analogues
UY33462A (es) 2010-06-23 2012-01-31 Zealand Pharma As Analogos de glucagon
RU2013102991A (ru) * 2010-06-24 2014-08-10 Индиана Юниверсити Рисерч Энд Текнолоджи Корпорейшн Связанные с дипептидом лекарственные средства
SG186764A1 (en) 2010-06-24 2013-02-28 Zealand Pharma As Glucagon analogues
WO2011163462A2 (en) 2010-06-24 2011-12-29 Indiana University Research And Technology Corporation Amide-based insulin prodrugs
KR20140043709A (ko) 2011-01-20 2014-04-10 질랜드 파마 에이/에스 아실화 글루카곤 유사체와 인슐린 유사체의 조합
JP2014509603A (ja) * 2011-03-15 2014-04-21 ノヴォ ノルディスク アー／エス システイン置換を含むヒトインスリン類似体およびヒトインスリン誘導体
US9260503B2 (en) 2011-06-15 2016-02-16 Novo Nordisk A/S Multi-substituted insulins
SI2723367T1 (sl) 2011-06-22 2017-08-31 Indiana University Research And Technology Corporation Koagonisti receptorja glukanona/GLP-1
CN104114183A (zh) 2011-12-20 2014-10-22 印第安纳大学研究及科技有限公司 用于治疗糖尿病的基于ctp的胰岛素类似物
TWI689515B (zh) 2012-05-03 2020-04-01 丹麥商西蘭製藥公司 Ｇｉｐ-ｇｌｐ-１雙重促效劑化合物及方法
KR102129235B1 (ko) 2012-07-23 2020-07-06 질랜드 파마 에이/에스 글루카곤 유사체
TWI608013B (zh) 2012-09-17 2017-12-11 西蘭製藥公司 升糖素類似物
WO2014052451A2 (en) 2012-09-26 2014-04-03 Indiana University Research And Technology Corporation Insulin analog dimers
CA2890048C (en) 2012-12-03 2022-05-03 Merck Sharp & Dohme Corp. O-glycosylated carboxy terminal portion (ctp) peptide-based insulin and insulin analogues
US10421795B2 (en) 2012-12-17 2019-09-24 Merck Sharp & Dohme Corp. Process for purifying insulin and analogues thereof
BR112015023071A2 (pt) 2013-03-14 2017-07-18 Univ Indiana Res & Tech Corp conjugados de insulina-incretina
MX366852B (es) 2013-10-04 2019-07-25 Merck Sharp & Dohme Conjugados de insulina sensibles a glucosa.
US9896495B2 (en) 2013-10-17 2018-02-20 Zealand Pharma A/S Acylated glucagon analogues
US9988429B2 (en) 2013-10-17 2018-06-05 Zealand Pharma A/S Glucagon analogues
EA035688B1 (ru) 2013-11-06 2020-07-27 Зилэнд Фарма А/С Соединения, которые представляют собой тройные агонисты глюкагона, glp-1 и gip
WO2015067715A2 (en) 2013-11-06 2015-05-14 Zealand Pharma A/S Gip-glp-1 dual agonist compounds and methods
WO2015084694A2 (en) 2013-12-04 2015-06-11 Merck Sharp & Dohme Corp. Method for preparing crystalline insulin
EP3077008B1 (en) 2013-12-06 2023-10-04 Jie Han Bioreversable promoieties for nitrogen-containing and hydroxyl-containing drugs
MY186251A (en) 2014-01-20 2021-06-30 Hanmi Pharm Ind Co Ltd Long-acting insulin and use thereof
AR099569A1 (es) 2014-02-28 2016-08-03 Novo Nordisk As Derivados de insulina y los usos médicos de estos
US10407483B2 (en) 2014-03-14 2019-09-10 Merck Sharp & Dohme Corp. Purifying insulin using cation exchange and reverse phase chromatography in the presence of an organic modifier and elevated temperature
AR100639A1 (es) 2014-05-29 2016-10-19 Hanmi Pharm Ind Co Ltd Composición para tratar diabetes que comprende conjugados de análogos de insulina de acción prolongada y conjugados de péptidos insulinotrópicos de acción prolongada
AR100695A1 (es) 2014-05-30 2016-10-26 Hanmi Pharm Ind Co Ltd Composición para el tratamiento de diabetes mellitus que comprende insulina y un agonista dual glp-1 / glucagón
EP3171888B1 (en) 2014-07-21 2022-12-28 Merck Sharp & Dohme LLC Chromatography process for purification of inlsulin and insulin analogs
CN108271356A (zh) * 2014-09-24 2018-07-10 印第安纳大学研究及科技有限公司 肠降血糖素-胰岛素缀合物
ES2947409T3 (es) * 2014-09-24 2023-08-08 Univ Indiana Res & Tech Corp Profármacos de insulina a base de amida lipídica
EP3212218B1 (en) 2014-10-29 2021-06-30 Zealand Pharma A/S Gip agonist compounds and methods
CR20170208A (es) 2014-11-21 2017-07-17 Merck Sharp & Dohme Agonistas parciales del receptor de insulina
US10562951B2 (en) 2015-03-10 2020-02-18 Merck Sharp & Dohme Corp. Process for preparing recombinant insulin using microfiltration
TWI707867B (zh) 2015-04-16 2020-10-21 丹麥商西蘭製藥公司 醯化之昇糖素類似物
UY36870A (es) 2015-08-28 2017-03-31 Hanmi Pharm Ind Co Ltd Análogos de insulina novedosos
US10745457B2 (en) 2015-09-02 2020-08-18 Merck Sharp & Dohme Corp. Process for obtaining insulin with correctly formed disulfide bonds
WO2017180988A2 (en) 2016-04-15 2017-10-19 Indiana University Research And Technology Corporation Fgf21 c-terminal peptide optimization
EP3448417B1 (en) 2016-04-26 2025-11-12 Merck Sharp & Dohme LLC Insulin dimer-incretin conjugates
WO2017205191A1 (en) 2016-05-24 2017-11-30 Merck Sharp & Dohme Corp. Insulin receptor partial agonists and glp-1 analogues
EP3463413A4 (en) 2016-05-25 2020-03-04 Merck Sharp & Dohme Corp. INSULIN RECEPTOR PART AGONISTS
HRP20220479T1 (hr) 2016-06-01 2022-05-27 Athira Pharma, Inc. Spojevi
WO2017210168A1 (en) * 2016-06-02 2017-12-07 Indiana University Research And Technology Corporation Aqueously soluble and chemically stable depsi glucagon agonists
EP3272877A1 (en) 2016-07-18 2018-01-24 ETH Zurich B-cell-mimetic cells
WO2018015330A1 (en) 2016-07-18 2018-01-25 Eth Zurich B-cell-mimetic cells
EP3517544B1 (en) 2016-09-23 2025-01-08 Hanmi Pharm. Co., Ltd. Insulin analog having reduced binding force to insulin receptor, and use thereof
WO2018165290A1 (en) * 2017-03-07 2018-09-13 Case Western Reserve University Single-chain insulin analogues stabilized by a fourth disulfide bridge
EP3604328A4 (en) 2017-03-23 2021-01-06 Hanmi Pharm. Co., Ltd. INSULIN ANALOGUE COMPLEX WITH REDUCED AFFINITY FOR THE INSULIN RECEPTOR AND USE OF IT
US11041009B2 (en) 2017-03-23 2021-06-22 Merck Sharp & Dohme Corp. Glucose responsive insulin comprising a tri-valent sugar cluster for treatment of diabetes
EP3624828B1 (en) 2017-05-18 2024-08-07 Merck Sharp & Dohme LLC Pharmaceutical formulation comprising incretin-insulin conjugates
AU2018317810A1 (en) 2017-08-17 2020-03-19 Novo Nordisk A/S Novel acylated insulin analogues and uses thereof
SG11202106168VA (en) 2018-12-11 2021-07-29 Sanofi Sa Insulin analogs having reduced insulin receptor binding affinity
WO2020247297A1 (en) 2019-06-06 2020-12-10 Merck Sharp & Dohme Corp. Glucose-responsive insulin conjugates
MX2022014907A (es) * 2020-05-26 2023-01-04 Univ Indiana Res & Tech Corp Analogos de la hormona paratiroidea para el tratamiento del hipoparatiroidismo.

Family Cites Families (61)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3740385A (en) 1970-05-07 1973-06-19 M Ondetti N-terminal derivatives of secretin
US4275152A (en) 1977-02-03 1981-06-23 Eastman Kodak Company Hydrolysis of protein-bound cholesterol esters
PT83613B (en) 1985-10-28 1988-11-21 Lilly Co Eli Process for the selective chemical removal of a protein amino-terminal residue
JPS63502716A (ja) 1986-03-07 1988-10-13 マサチューセッツ・インステチュート・オブ・テクノロジー 糖タンパク安定性の強化方法
US4741897A (en) 1986-07-08 1988-05-03 Baxter Travenol Thyroxine analogs and reagents for thyroid hormone assays
US4876242A (en) 1987-09-21 1989-10-24 Merck & Co., Inc. Human insulin-like growth factor analoges with reduced binding to serum carrier proteins and their production in yeast
GB8728561D0 (en) 1987-12-07 1988-01-13 Glaxo Group Ltd Chemical compounds
US5514646A (en) 1989-02-09 1996-05-07 Chance; Ronald E. Insulin analogs modified at position 29 of the B chain
EP0469084B1 (en) 1989-04-20 1995-04-05 Mount Sinai School Of Medicine Of The City University Of New York Hepatospecific insulin analogues
US5268453A (en) 1991-08-08 1993-12-07 Scios Inc. Tissue-selective insulin analogs
US5359030A (en) 1993-05-10 1994-10-25 Protein Delivery, Inc. Conjugation-stabilized polypeptide compositions, therapeutic delivery and diagnostic formulations comprising same, and method of making and using the same
US6476290B1 (en) 1995-04-19 2002-11-05 Dalhousie University Transgenic tilapia comprising a humanized insulin gene
EP0741188A3 (en) 1995-05-05 1999-07-14 Eli Lilly And Company Single chain insulin with high bioactivity
US6180767B1 (en) 1996-01-11 2001-01-30 Thomas Jefferson University Peptide nucleic acid conjugates
IL128828A0 (en) 1996-09-09 2000-01-31 Zealand Pharmaceuticals As Peptide prodrugs containing an alpha-hydroxy acid linker
UA65549C2 (uk) 1996-11-05 2004-04-15 Елі Ліллі Енд Компані Спосіб регулювання ожиріння шляхом периферійного введення аналогів та похідних glp-1 (варіанти) та фармацевтична композиція
SK12412000A3 (sk) 1998-02-23 2002-05-09 Neurocrine Biosciences, Inc. Metódy liečenia diabetu použitím peptidových analógov inzulínu
IL138214A0 (en) 1998-03-09 2001-10-31 Zealand Pharmaceuticals As Pharmacolgically active peptide conjugates having a reduced tendency towards enzymatic hydrolysis
US20030236190A1 (en) 1998-09-02 2003-12-25 Renuka Pillutla Isulin and IGF-1 receptor agonists and antagonists
US6875741B2 (en) 1998-09-02 2005-04-05 Renuka Pillutla Insulin and IGF-1 receptor agonists and antagonists
DE19908041A1 (de) 1999-02-24 2000-08-31 Hoecker Hartwig Kovalent verbrückte Insulindimere
WO2000058360A2 (en) 1999-03-29 2000-10-05 Uutech Limited Analogs of gastric inhibitory peptide and their use for treatment of diabetes
US6746853B1 (en) 1999-05-19 2004-06-08 Xencor, Inc. Proteins with insulin-like activity useful in the treatment of diabetes
AUPQ661800A0 (en) 2000-03-31 2000-05-04 Metabolic Pharmaceuticals Limited Insulin-potentiating compounds
JP2004509079A (ja) 2000-08-02 2004-03-25 セラテクノロジーズ・インコーポレーテッド 効力が増大した修飾生体ペプチド
AU2001284697A1 (en) 2000-08-04 2002-02-18 Dmi Biosciences, Inc. Method of synthesizing diketopiperazines
US7052686B2 (en) 2000-09-29 2006-05-30 Schering Corporation Pegylated interleukin-10
KR100449454B1 (ko) 2000-10-02 2004-09-21 이현철 단일사슬 인슐린 유도체의 유전자를 포함하는 당뇨병치료용 벡터
EP1243276A1 (en) 2001-03-23 2002-09-25 Franciscus Marinus Hendrikus De Groot Elongated and multiple spacers containing activatible prodrugs
MXPA03009566A (es) 2001-04-19 2004-12-06 Scripps Research Inst Metodos y composicion para la produccion de pares trna-aminoaciltrna sintetasa ortogonales.
BR0215029A (pt) * 2001-12-20 2005-12-20 Lilly Co Eli Molécula de insulina, uso da mesma, composição, uso desta, microcristal, processo para prepará-lo, uso deste, e, métodos para preparar uma molécula de insulina, para tratar hiperglicemia, e para tratar diabetes mellitus
GB2392994A (en) * 2002-05-30 2004-03-17 Medivance Instr Ltd Apparatus and method for monitoring the efficacy of an X-ray or photographic development process
FR2842209B1 (fr) 2002-07-09 2007-11-23 Nouvelle protease aspartique dite saspase et son utilisation dans le domaine cosmetique et therapeutique
AU2004204494B2 (en) 2003-01-09 2011-09-29 Macrogenics, Inc. Identification and engineering of antibodies with variant Fc regions and methods of using same
WO2004067548A2 (en) 2003-01-31 2004-08-12 Theratechnologies Inc. Chemically modified metabolites of regulatory peptides and methods of producing and using same
EP1626981A4 (en) 2003-03-04 2006-11-22 Biorexis Pharmaceutical Corp PROTEINS PROTECTED AGAINST DIPEPTIDYLPEPTIDASE
PL1605897T3 (pl) 2003-03-19 2012-12-31 Lilly Co Eli Związki będące połączeniem GLP-1 z poli(glikolem etylenowym)
EP1620118B1 (en) 2003-04-08 2014-06-18 Yeda Research And Development Co., Ltd. Reversible pegylated drugs
TWI353991B (en) 2003-05-06 2011-12-11 Syntonix Pharmaceuticals Inc Immunoglobulin chimeric monomer-dimer hybrids
WO2005027978A2 (en) 2003-09-19 2005-03-31 Novo Nordisk A/S Albumin-binding derivatives of therapeutic peptides
WO2005035003A2 (en) 2003-09-22 2005-04-21 Dihedron Corporation Compositions and methods for increasing drug efficiency
PL2332968T3 (pl) 2003-11-05 2017-08-31 Dana-Farber Cancer Institute, Inc. Stabilizowane alfa-helikalne peptydy i ich zastosowania
EP1692168B1 (en) 2003-12-03 2011-07-20 Novo Nordisk A/S Single-chain insulin
EP1812082B1 (en) 2004-10-21 2013-08-14 IGF Oncology, LLC Toxins and radionuclides coupled to IGF-1 receptor ligands for the treatment of cancer
US7521211B2 (en) 2005-04-05 2009-04-21 Regeneron Pharmaceuticals, Inc IGF-1 and IGF-2 chimeric polypeptides and therapeutic uses thereof
US7846445B2 (en) 2005-09-27 2010-12-07 Amunix Operating, Inc. Methods for production of unstructured recombinant polymers and uses thereof
JP2009527526A (ja) * 2006-02-21 2009-07-30 ノボ・ノルデイスク・エー／エス 単鎖インスリンのアナログとその製薬的製剤
EP1996224B1 (en) 2006-03-15 2012-11-07 Novo Nordisk A/S Mixtures of amylin and insulin
CA2660835A1 (en) 2006-08-17 2008-02-21 Amylin Pharmaceuticals, Inc. Dpp-iv resistant gip hybrid polypeptides with selectable propperties
CL2007002502A1 (es) 2006-08-31 2008-05-30 Hoffmann La Roche Variantes del factor de crecimiento similar a insulina-1 humano (igf-1) pegilados en lisina; metodo de produccion; proteina de fusion que la comprende; y su uso para tratar la enfermedad de alzheimer.
CA2663083A1 (en) 2006-09-08 2008-03-13 Ambrx, Inc. Modified human plasma polypeptide or fc scaffolds and their uses
CN103298935A (zh) 2007-08-15 2013-09-11 阿穆尼克斯公司 用于改善生物活性多肽性能的组合物和方法
EP2036923A1 (en) 2007-09-11 2009-03-18 Novo Nordisk A/S Improved derivates of amylin
EP2036539A1 (en) 2007-09-11 2009-03-18 Novo Nordisk A/S Stable formulations of amylin and its analogues
MX338336B (es) 2007-11-20 2016-04-07 Ambrx Inc Polipeptidos de insulina modificados y sus usos.
WO2009099763A1 (en) 2008-01-30 2009-08-13 Indiana University Research And Technology Corporation Ester-based peptide prodrugs
JP5588354B2 (ja) 2008-02-01 2014-09-10 アセンディス ファーマ エー／エス 自己切断可能なリンカーを含むプロドラッグ
EP2356139A4 (en) 2008-07-23 2013-01-09 Harvard College LIGURE COMBINED POLYPEPTIDES
WO2010071807A1 (en) 2008-12-19 2010-06-24 Indiana University Research And Technology Corporation Amide based glucagon superfamily peptide prodrugs
CN102300580A (zh) 2008-12-19 2011-12-28 印第安纳大学研究及科技有限公司 二肽连接的药剂
US8778872B2 (en) 2010-06-24 2014-07-15 Indiana University Research And Technology Corporation Amide based glucagon superfamily peptide prodrugs

Also Published As

Publication number Publication date
AU2009335715B2 (en) 2016-09-15
EP2376521B1 (en) 2016-04-13
AU2009335715A1 (en) 2010-07-15
CN102245624B (zh) 2016-08-10
EP2376521A4 (en) 2014-06-25
EP2376521A1 (en) 2011-10-19
US20110257076A1 (en) 2011-10-20
CN102245624A (zh) 2011-11-16
US8697632B2 (en) 2014-04-15
CA2744558A1 (en) 2010-07-15
WO2010080609A1 (en) 2010-07-15
JP2012512901A (ja) 2012-06-07

Similar Documents

Publication Publication Date Title
JP5755566B2 (ja) アミド系インスリンプロドラッグ
CA2802485C (en) Single chain insulin agonists exhibiting high activity at the insulin receptor
EP2585102B1 (en) Amide-based insulin prodrugs
JP5789515B2 (ja) インスリン類似体
JP2012512900A (ja) インスリン受容体に対して高い活性を示すｙｌ系インスリン様増殖因子
JP6701208B2 (ja) 脂質化アミド系インスリンプロドラッグ
JP2015508285A (ja) 糖尿病治療のためのｃｔｐ系インスリンアナローグ
WO2011163460A1 (en) Yl-based insulin-like growth factors exhibiting high activity at the insulin receptor
WO2017210077A1 (en) Single chain insulin prodrugs

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20121218

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20121218

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20140610

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20140910

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20140918

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20141010

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20141020

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20141110

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20150428

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20150527

R150 Certificate of patent or registration of utility model

Ref document number: 5755566

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

S531 Written request for registration of change of domicile

Free format text: JAPANESE INTERMEDIATE CODE: R313531

R350 Written notification of registration of transfer

Free format text: JAPANESE INTERMEDIATE CODE: R350

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

LAPS Cancellation because of no payment of annual fees